Management of and risk factors related to hepatotoxicity during tuberculosis treatment;Tüberküloz tedavisinde hepatotoksisite risk faktörleri ve yönetimi

Tuberkuloz ve Toraks

Volumn 60, Issue 2, 2012, Pages 136-144

  Babalik, Aylin ^a   Arda, Hülya ^a   Bakirci, Nadi ^b   Aǧca, Sinem ^a   Oruç, Korkmaz ^a   Kiziltaş, Şule ^a   Çetintaş, Gülgün ^a   Çalişir, Haluk C ^a  

^a Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital   (Turkey)

^b ACIBADEM UNIVERSITY   (Turkey)

Author keywords

Hepatotoxicity; Management; Risk factors; Tuberculosis treatment

Indexed keywords

ETHAMBUTOL; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; COMORBIDITY; DISEASE DURATION; DISEASE PREDISPOSITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; PROGNOSIS; RECURRENT INFECTION; RISK ASSESSMENT; TOXIC HEPATITIS; TUBERCULOSIS;

EID: 84863938811     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: 10.5578/tt.3053     Document Type: Article

References (18)

1. WHO/HTM/TB/2009.420: Treatment of Tuberculosis: Guidelines for National Programmes. Fourth edition.
2. Jose A, Caminero Luna A. Tuberculosis Guide for Specialist Physicians, International Union Against Tuberculosis and Lung Disease 68 boulevard Saint Michel, 75006 Paris France 2003: 158.
3. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22: 145-55.
4. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, et al; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-54.
5. Saukkonen JL, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-52.
6. rd ed. World Health Organization-Geneva 2003.
7. Guidelines for the programmatic management of drugresistant tuberculosis. WHO/HTM/TB/2006.361.
8. Tost JR, Vidal R. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis 2005; 9: 534-40.
9. Kiter G, Coskunol I. Hepatotoxicity during the anti-tuberculosis treatment: a retrospective survey of 5-year-period. Tuberk Toraks 2000; 48: 20-5.
10. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-71.
11. Chang KC, Leung CC, Yew WW, Lau TY, Tam CM. Tuberculosis and chest service, centre for health hepatotoxicity of pyrazinamide cohort and case-control analyses. Am J Respir Crit Care Med 2008; 177: 1391-6.
12. Døssing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996; 77: 335-40.
13. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-9.
14. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004; 38: 1074-9.
15. Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 2002; 6: 699-705.
16. Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CL, Lin TP, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997; 12: 87-91.
17. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-48.
18. TahaoGlu K, Ata CG, Sevim T. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001; 5: 65-9.